Capricor Therapeutics Provides Regulatory Update On Deramiocel BLA For Duchenne Muscular Dystrophy
View all comments(0)
July 11 (Reuters) - Capricor Therapeutics Inc CAPR.O:
CAPRICOR THERAPEUTICS PROVIDES REGULATORY UPDATE ON DERAMIOCEL BLA FOR DUCHENNE MUSCULAR DYSTROPHY
CAPRICOR THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER TO CAPRICOR
CAPRICOR THERAPEUTICS INC - TO RESUBMIT BLA WITH PHASE 3 DATA IN Q3 2025
CAPRICOR THERAPEUTICS INC - FDA ADVISES CAPRICOR TO REQUEST MEETING FOR APPROVAL
CAPRICOR THERAPEUTICS: FDA SAID DERAMIOCEL BLA DOES NOT MEET STATUTORY REQUIREMENT FOR SUBSTANTIAL EVIDENCE OF EFFECTIVENESS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.